Skip to main content
Caplight Logo









ProteoWise

ProteoWise

Private
New Haven, ConnecticutHealthcare & Life Scienceshttps://proteowise.com/

Last Round

VC Round

Dec 13, 2024

Total Funding Raised

$6.55M

Company Overview

ProteoWise is a biotech company that has developed a high-throughput proteomics platform to enable faster and more cost-effective protein analysis for researchers.

Sector

Healthcare & Life Sciences

Verticals

Biotech Equipment, Medical Devices, Biotechnology

Business Model

B2B

Customer Profile

Hardware Sales, Hardware + Subscription, Government Contracts

AI Layer

Application

Keywords

proteomics instrumentprotein analysismultiplex protein analysiswestern blot alternativedigital western blotautomated proteomicsnanoscale protein capture3D-NPChigh-throughput proteomicsprotein quantificationbenchtop instrumentlife science toolsbiotech equipmentlab consumablesdrug discoverycomputer vision

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ProteoWise Comparables

Compare ProteoWise with similar companies based on industry and business-model similarity.

ProteoWise comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
NanoMosaic
83%
Bio-Techne Corporation
76%
Bio-Rad Laboratories
73%

ProteoWise Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundDec 13, 2024
VC RoundApr 1, 2021
GrantSep 1, 2020
Series AMar 27, 2020

ProteoWise Investors

Notable investors and investment history

ProteoWise investors
InvestorRounds
Connecticut InnovationsVC Round, Series A
Co-Win VenturesSeries A
Taihill VentureVC Round, Series A
Foothill VenturesSeries A, VC Round
National Institute on AgingGrant
UniWill VenturesVC Round, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 3, 2025

    Monthly visitors grew 2605% MoM, from 20 to 541.

  • Dec 13, 2024

    $10M round led by Connecticut Innovations.

ProteoWise Filings

Explore SEC and related filing metadata, where available.

ProteoWise filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about ProteoWise's valuation, stock price, and market status.

Is ProteoWise a public or private company?

ProteoWise is a private company.

What is the current stock price of ProteoWise?

ProteoWise is a private company with no public stock price. No recent secondary market data is available.

How much is ProteoWise worth (valuation)?

Valuation information for ProteoWise is not publicly available.

Can I buy ProteoWise stock?

ProteoWise shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was ProteoWise's last funding round?

ProteoWise's most recent funding round was VC Round on December 13, 2024.

Who are the main investors in ProteoWise?

Key investors in ProteoWise include Connecticut Innovations.

Will ProteoWise IPO soon?

No public IPO plans have been announced for ProteoWise.

How can I track ProteoWise secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ProteoWise's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersNew Haven, Connecticut
Employee Range13
Year Founded2018
Last FundingDec 13, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?